Eli Lilly and Company And Amylin Pharmaceuticals, Inc. Release: BYETTA(R) Extension Study Shows Sustained Improvements In Blood Glucose Control And Progressive Weight Loss After Two Years

WASHINGTON, D.C., June 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) and Eli Lilly and Company (NYSE: LLY - News) today announced two-year study results showing that BYETTA® (exenatide) injection sustained improvements in blood sugar control and reduced body weight in people with type 2 diabetes who previously did not achieve adequate control of their blood sugar on common oral medications. These findings were presented at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) in Washington, D.C.